Plain-English translation of NCT06281834 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing how , a common HIV medication, works in children's bodies when they also take medication to prevent tuberculosis. Researchers want to make sure the two medications work well together and don't interfere with each other. The study will measure how much of each medication stays in children's blood over time.
Children with HIV often need medication to prevent tuberculosis, but doctors aren't always sure if these two treatments interact in ways that make either one less effective. This study will help doctors understand the best way to safely give both medications together.
You likely qualify if…
You likely don't qualify if…
Your child will take standard HIV medication and TB prevention medication as prescribed by their doctor. Over 48 weeks, your child will have blood drawn three times to measure how much medication is in their body—once with intensive sampling and twice with smaller samples. You'll also have regular check-ups to watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Nigeria
Safety & dosing
Sponsor
Brigham and Women's Hospital
Collaborators
APIN Public Health Initiatives, University of Cape Town
Enrollment target
~25 participants
Started
November 2024
Primary completion
February 2027
Age range
4 Weeks – 11 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Holly Rawizza, MD, MPH
Brigham and Women's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.